Chika Nagahisa
Papers
2
Total Citations
7
H-Index
2
About
Dr. Chika Nagahisa is a pioneering oncologic surgeon whose work focuses on the intersection of immunotherapy and complex surgical oncology, particularly in genitourinary cancers. Her major contributions lie in demonstrating the feasibility and efficacy of combining targeted therapies and immune checkpoint inhibitors with radical surgical interventions for advanced-stage disease. Notably, her 2024 study on "Advanced Renal Cell Carcinoma With Inferior Vena Cava Thrombus Treated With a Combination of Preoperative Lenvatinib and Pembrolizumab" (5 citations) was the first to report the successful use of this specific drug combination as a neoadjuvant strategy, enabling safe resection of life-threatening tumor thrombi. This work challenges the traditional paradigm that such extensive disease is inoperable. Additionally, her 2023 investigation into "Efficacy of Combined Pembrolizumab and Pelvic Radiotherapy for Bladder Cancer With Rectal Metastases" (2 citations) offers a novel, non-surgical salvage option for an extremely rare and previously fatal metastatic pattern. Though early in their citation lifecycle, these studies represent critical proof-of-concept data that are reshaping treatment algorithms for the most challenging cases of renal and bladder cancer, offering new hope for patients with historically poor prognoses.
Research Focus
Key Achievements
Top Papers
- 1
- 2